84 related articles for article (PubMed ID: 2143499)
1. Lack of effect of dehydroepiandrosterone in obese men.
Usiskin KS; Butterworth S; Clore JN; Arad Y; Ginsberg HN; Blackard WG; Nestler JE
Int J Obes; 1990 May; 14(5):457-63. PubMed ID: 2143499
[TBL] [Abstract][Full Text] [Related]
2. Dehydroepiandrosterone sulfate levels in women. Relationships with body mass index, insulin and glucose levels.
Al-Harithy RN
Saudi Med J; 2003 Aug; 24(8):837-41. PubMed ID: 12939667
[TBL] [Abstract][Full Text] [Related]
3. Dehydroepiandrosterone sulphate, body fat distribution and insulin in obese men.
Herranz L; Megia A; Grande C; González-Gancedo P; Pallardo F
Int J Obes Relat Metab Disord; 1995 Jan; 19(1):57-60. PubMed ID: 7719392
[TBL] [Abstract][Full Text] [Related]
4. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men.
Nestler JE; Barlascini CO; Clore JN; Blackard WG
J Clin Endocrinol Metab; 1988 Jan; 66(1):57-61. PubMed ID: 2961787
[TBL] [Abstract][Full Text] [Related]
5. Effects of a reduction in circulating insulin by metformin on serum dehydroepiandrosterone sulfate in nondiabetic men.
Nestler JE; Beer NA; Jakubowicz DJ; Beer RM
J Clin Endocrinol Metab; 1994 Mar; 78(3):549-54. PubMed ID: 8126125
[TBL] [Abstract][Full Text] [Related]
6. Disparate effects of insulin reduction with diltiazem on serum dehydroepiandrosterone sulfate levels in obese hypertensive men and women.
Beer NA; Jakubowicz DJ; Beer RM; Nestler JE
J Clin Endocrinol Metab; 1994 Oct; 79(4):1077-81. PubMed ID: 7962276
[TBL] [Abstract][Full Text] [Related]
7. Role of DHEA-S on body fat distribution: gender- and depot-specific stimulation of adipose tissue lipolysis.
Hernández-Morante JJ; Pérez-de-Heredia F; Luján JA; Zamora S; Garaulet M
Steroids; 2008 Feb; 73(2):209-15. PubMed ID: 18063002
[TBL] [Abstract][Full Text] [Related]
8. Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women.
Diamond P; Cusan L; Gomez JL; Bélanger A; Labrie F
J Endocrinol; 1996 Sep; 150 Suppl():S43-50. PubMed ID: 8943786
[TBL] [Abstract][Full Text] [Related]
9. Disparate effects of weight reduction by diet on serum dehydroepiandrosterone-sulfate levels in obese men and women.
Jakubowicz DJ; Beer NA; Beer RM; Nestler JE
J Clin Endocrinol Metab; 1995 Nov; 80(11):3373-6. PubMed ID: 7593454
[TBL] [Abstract][Full Text] [Related]
10. The association of dehydroepiandrosterone, obesity, waist-hip ratio and insulin resistance with fatty liver in postmenopausal women--a hyperinsulinemic euglycemic insulin clamp study.
Saruç M; Yüceyar H; Ayhan S; Türkel N; Tuzcuoglu I; Can M
Hepatogastroenterology; 2003; 50(51):771-4. PubMed ID: 12828082
[TBL] [Abstract][Full Text] [Related]
11. Dehydroepiandrosterone replacement in healthy men with age-related decline of DHEA-S: effects on fat distribution, insulin sensitivity and lipid metabolism.
Jedrzejuk D; Medras M; Milewicz A; Demissie M
Aging Male; 2003 Sep; 6(3):151-6. PubMed ID: 14628495
[TBL] [Abstract][Full Text] [Related]
12. The estrogen antagonist EM-652 and dehydroepiandrosterone prevent diet- and ovariectomy-induced obesity.
Lemieux C; Picard F; Labrie F; Richard D; Deshaies Y
Obes Res; 2003 Mar; 11(3):477-90. PubMed ID: 12634448
[TBL] [Abstract][Full Text] [Related]
13. Muscle tissue in obesity with different distribution of adipose tissue. Effects of physical training.
Krotkiewski M; Björntorp P
Int J Obes; 1986; 10(4):331-41. PubMed ID: 3533812
[TBL] [Abstract][Full Text] [Related]
14. Dehydroepiandrosterone in morbidly obese adolescents: effects on weight, body composition, lipids, and insulin resistance.
Vogiatzi MG; Boeck MA; Vlachopapadopoulou E; el-Rashid R; New MI
Metabolism; 1996 Aug; 45(8):1011-5. PubMed ID: 8769361
[TBL] [Abstract][Full Text] [Related]
15. Androgen treatment of middle-aged, obese men: effects on metabolism, muscle and adipose tissues.
Mårin P; Krotkiewski M; Björntorp P
Eur J Med; 1992 Oct; 1(6):329-36. PubMed ID: 1341460
[TBL] [Abstract][Full Text] [Related]
16. Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients.
Nam SY; Kim KR; Cha BS; Song YD; Lim SK; Lee HC; Huh KB
Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1101-7. PubMed ID: 11477493
[TBL] [Abstract][Full Text] [Related]
17. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.
Stomati M; Monteleone P; Casarosa E; Quirici B; Puccetti S; Bernardi F; Genazzani AD; Rovati L; Luisi M; Genazzani AR
Gynecol Endocrinol; 2000 Oct; 14(5):342-63. PubMed ID: 11109974
[TBL] [Abstract][Full Text] [Related]
18. Anti-obesity effect of two different levels of dehydroepiandrosterone in lean and obese middle-aged female Zucker rats.
Cleary MP; Zisk JF
Int J Obes; 1986; 10(3):193-204. PubMed ID: 2944850
[TBL] [Abstract][Full Text] [Related]
19. Weight loss increased serum adiponectin but decreased lipid levels in obese subjects whose body mass index was lower than 30 kg/m².
Lang HF; Chou CY; Sheu WH; Lin JY
Nutr Res; 2011 May; 31(5):378-86. PubMed ID: 21636016
[TBL] [Abstract][Full Text] [Related]
20. Short-term dehydroepiandrosterone treatment increases platelet cGMP production in elderly male subjects.
Martina V; Benso A; Gigliardi VR; Masha A; Origlia C; Granata R; Ghigo E
Clin Endocrinol (Oxf); 2006 Mar; 64(3):260-4. PubMed ID: 16487434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
